Thyroid hormone, immunoglobin and complements for predicting hepatocellular carcinoma development in patients with hepatitis B virus-related liver cirrhosis

Table 2 Characteristics of patients with hepatitis B virus-related liver cirrhosis (internal subgroup)

Variables	Patients did not develope HCC (n = 88)	Patients developed HCC (n = 12)	Z or χ²	P value
Age (years)	50.5 (46, 61.8)	63 (55, 67.8)	3.010	< 0.01
Male	58 (65.9)	9 (75.0)	0.395	0.75
Decompensated cirrhosis	30 (34.1)	10 (83.3)	10.669	< 0.01
Diabetes	22 (25)	6 (50)	3.274	0.09
Alanine transaminase (U/L)	35 (21, 68.8)	28.5 (18.8, 54.5)	0.960	0.34
Aspartate transaminase (U/L)	36 (25, 57.8)	43.5 (33, 54.5)	0.642	0.52
Gamma-glutamyl transpeptidase (U/L)	60 (28.3, 90)	130.5 (28.5, 169.8)	1.681	0.09
Total bilirubin (µmol/L)	21.8 (15.6, 30.7)	24.5 (16.9, 32.2)	0.536	0.59
Albumin (g/L)	40.3 (33.8, 43.9)	40.2 (33.2, 44.3)	0.042	0.97
Creatinine (µmol/L)	77.4 (70.1, 88.9)	81.3 (63.2, 90.8)	0.127	0.90
International normalized ratio	1.1 (1.0, 1.2)	1.1 (0.9, 1.2)	0.244	0.81
Platelet (E+09/L)	103.5 (65.5, 142.8)	74 (51.5, 90)	2.127	0.03
Total triiodothyronine (nmol/L)	1.6 (1.3, 1.9)	1.5 (1.3, 1.7)	1.008	0.31
Total tetraiodothyronine (nmol/L)	118.2 (102.5, 134.3)	113.2 (94.4, 135.5)	0.525	0.60
Free triiodothyronine (pmol/L)	4.8 (4.3, 5.3)	4.9 (4.3, 5.5)	0.106	0.92
Free tetraiodothyronine (pmol/L)	11.2 (9.8, 12.4)	12.2 (9.6, 13.1)	0.981	0.33
Thyroid-stimulating hormone (μIU/mL)	1.4 (1.1, 2.0)	1.3 (1.0, 2.6)	0.377	0.71
IgM (g/L)	1.4 (0.9, 1.8)	1.2 (1.0, 1.9)	0.048	0.96
IgA (g/L)	2.8 (2.2, 3.8)	2.8 (1.9, 4.1)	0.191	0.85
IgG (g/L)	14.9 (12.9, 18.8)	15.5 (11.1, 19.3)	0.472	0.64
Complement C3 (g/L)	0.8 (0.7, 0.9)	0.8 (0.6, 1.0)	0.074	0.94
Complement C4 (g/L)	0.2 (0.1, 0.2)	0.2 (0.1, 0.2)	0.871	0.38
Duration of follow-up (months)	32 (26.3, 36.8)	21.5 (12.5, 26.3)	3.759	< 0.01

Comparison was conducted by a Mann-Whitney U test (median and interquartile range) for continuous variables, and χ² test for categorial values. HCC: Hepatocellular carcinoma; Ig: Immunoglobulin.